SHAREHOLDER ALERT: Weiss Law Investigates Opiant Pharmaceuticals, Inc.

NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Opiant Pharmaceuticals, Inc. ("Opiant" or the "Company") (NASDAQ: OPNT), in connection with its takeover by Indivior PLC. Under the terms of the merger agreement, shareholders will receive $20.00 cash for each Opiant share, plus up to $8.00 per share in contingent value rights ("CVRs") if revenue milestones are achieved by Opiant's lead asset (OPNT003) in the seven years after the U.S. commercial launch of OPNT003. 

If you own Opiant shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://www.weisslaw.co/news-and-cases/opnt
Or please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7^th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
[email protected]

Weiss Law is investigating whether (i) Opiant's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $20.00 per-share merger consideration and CVR adequately compensates Opiant's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. Notably, the merger consideration is below the $41 median price target set by analysts, and at least one analyst set a price target for the Company of $42 per share, $22.00 above the per-share merger consideration.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]

SOURCE Weiss Law

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED